Product Description: Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Houghton PJ, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2010 Jul 1;54(7):921-6.
CAS Number: 947687-12-9
Molecular Weight: N/A
Compound Purity: 97.57
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Others